Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well

Rhea-AI Summary

Northwest Biotherapeutics (OTCQB: NWBO) presented findings on its DCVax^®-L at the Frontiers of Cancer Immunotherapy Conference on May 10, 2022. Dr. Paul Mulholland from University College Hospital highlighted data on the personalized immune therapy for glioblastoma, a lethal brain cancer. The company's lead program involves a 331-patient Phase III trial targeting newly diagnosed glioblastoma patients. This approach aims to offer effective cancer treatment with fewer toxicities compared to traditional therapies.

Positive

• Successful presentation of DCVax^®-L data at a major conference.
• Ongoing Phase III trial with 331 patients targeting glioblastoma.

Negative

• None.

BETHESDA, Md., May 10, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax^® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made today at 11:10 a.m., at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.  The presentation will be made by Dr. Paul Mulholland of University College Hospital.  

This presentation can be viewed virtually by registering online at the Academy's website at ­­­ https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/summary

Additionally, the slides used in the presentation will be posted online concurrently with or promptly following the presentation at Virtualtrials.org/Dcvax. The slides will not be posted on the Company's website.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe.  The Company has a broad platform technology for DCVax^® dendritic cell-based vaccines.  The Company's lead program is a 331-patient Phase III trial of DCVax^®-L for newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease."  The Company has also developed DCVax^®-Direct for inoperable solid tumor cancers.  It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials.  The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania. 

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

CONTACTS         
Dave Innes
804-513-4758
dinnes@nwbio.com                                     

Les Goldman
240-234-0059
lgoldman@nwbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/presentation-about-phase-3-trial-of-dcvax-l-for-glioblastoma-today-at-new-york-academy-of-sciences-to-be-available-online-as-well-301544019.html

SOURCE Northwest Biotherapeutics

FAQ

What is the purpose of the DCVax^®-L trial by Northwest Biotherapeutics?

The DCVax^®-L trial aims to evaluate the effectiveness of personalized immune therapies in treating newly diagnosed glioblastoma.

What are the results presented at the Frontiers of Cancer Immunotherapy Conference?

The presentation discussed the findings from the Phase III trial of DCVax^®-L, focusing on its potential benefits in treating glioblastoma.

What are the next steps for Northwest Biotherapeutics after the presentation?

Northwest Biotherapeutics will continue its Phase III trial and analyze further data from the ongoing research.

How might the results of the DCVax^®-L trial impact the stock price of NWBO?

Positive trial results could boost investor confidence and potentially increase the stock price of NWBO.